A leading provider of low-enriched uranium (LEU), Centrus expanded in 2021 into high-assay, low-enriched uranium (HALEU), the nuclear fuel that many advanced nuclear reactors require. The U.S. Nuclear Regulatory Commission granted the company's request to produce HALEU at its Ohio facility, making it the first and only U.S. producer of HALEU.
Characterizing itself as the "only HALEU enricher in the Western World with entrenched first-mover advantages," Centrus believes there is a significant market opportunity for the material to be used in advanced nuclear reactors, amounting to $2.8 billion by 2030 and $8 billion by 2035.
Already, Centrus has inked HALEU supply agreements with several advanced nuclear reactor developers, including Oklo (OKLO +10.35%) for its Aurora powerhouse, TerraPower, and X-Energy (XE +3.60%).
With $3.1 billion in LEU backlog reflecting contracts through 2040 and robust HAELU potential, Centrus has a bright future. And profitable on a free cash flow basis -- it reported $31.3 million in free cash flow for 2025 -- makes the company even more attractive for risk-averse investors.